All data are based on the daily closing price as of October 8, 2025
e
Eisai
4523.TSE
31.30 USD
-0.84
-2.61%
Overview
Last close
31.30 usd
Market cap
8.83B usd
52 week high
44.70 usd
52 week low
24.09 usd
Target price
31.95 usd
Valuation
P/E
29.9335
Forward P/E
32.6797
Price/Sales
1.7332
Price/Book Value
1.6317
Enterprise Value
8.54B usd
EV/Revenue
1.6528
EV/EBITDA
12.4867
Key financials
Revenue TTM
5.26B usd
Gross Profit TTM
4.13B usd
EBITDA TTM
662.25M usd
Earnings per Share
1.07 usd
Dividend
1.05 usd
Total assets
9.78B usd
Net debt
-322.44M usd
About
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neuropathy; Jyseleca, a janus kinase inhibitor; Goofice for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, treatment for dementia; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.